1.
Vopr Onkol
; 56(5): 613-6, 2010.
Article
in Russian
| MEDLINE
| ID: mdl-21137245
ABSTRACT
Ninety-six patients with unresectable or metastatic colorectal cancer received first-line chemotherapy plus bevacizumab. The purpose of our study was to evaluate the safety and efficacy of the therapy. Median relapse-free survival lasted 10.4 months. Addition of bevacizumab was well tolerated and may be recommended for clinical use.
Subject(s)
Angiogenesis Inhibitors/adverse effects , Antibodies, Monoclonal/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Colorectal Neoplasms/drug therapy , Aged , Angiogenesis Inhibitors/administration & dosage , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal, Humanized , Bevacizumab , Colorectal Neoplasms/pathology , Female , Hematologic Diseases/chemically induced , Humans , Male , Middle Aged , Muscle Weakness/chemically induced , Nausea/chemically induced , Neoplasm Staging , Quality of Life , Stomatitis/chemically induced , Treatment Outcome , Vomiting/chemically induced
2.
Vopr Onkol
; 56(6): 700-3, 2010.
Article
in Russian
| MEDLINE
| ID: mdl-21395127
ABSTRACT
Four categories of patients with advanced gastric cancer treated with different regimens of chemotherapy: (1) PF cisplatin 100 mg/m2/day+5-fluorouracil 1000 mg/m2/day intravenous infusion (100 hrs); (2) carboplatin (AUC5)+5-fluorouracil 500 mg/m2/day intravenous infusion (2 hrs), days 1-3; (3) DCF, and (4) bevacizumab+PF.